Clinical Trials Logo

Fragile X Syndrome (FXS) clinical trials

View clinical trials related to Fragile X Syndrome (FXS).

Filter by:
  • None
  • Page 1

NCT ID: NCT04314856 Withdrawn - Clinical trials for Fragile X Syndrome (FXS)

Novel Clinical Target in Fragile X Syndrome

Start date: January 12, 2021
Phase: Phase 1
Study type: Interventional

Fragile X syndrome (FXS) is the most common genetic cause of autism spectrum disorder (ASD). The investigators wish to examine brain distribution of sigma-1 receptors in young adult males with FXS using 18F-FTC-146 PET. This project will study the distribution of sigma-1 receptors in 15 young (18-30 years) male adults with FXS compared to 5 healthy adult volunteers.

NCT ID: NCT04308954 Terminated - Clinical trials for Fragile X Syndrome (FXS)

Neuroimaging GABA Physiology in Fragile X Syndrome

Start date: November 1, 2016
Phase: Phase 1
Study type: Interventional

The investigators wish to compare the brain distribution of GABA(A) receptors and GABA levels in young adult males with Fragile X Syndrome compared to idiopathic intellectual developmental disorder. The radiopharmaceutical [18F]flumazenil has been used to study GABA(A) receptor distribution in other genetic syndromes with autistic features; however, despite overwhelming evidence supporting the importance of the GABAergic system in FXS, no clinical investigation of this system in human FXS has been reported in the literature. Therefore, this study will provide the first in vivo comprehensive examination of the GABAergic system in FXS using hybrid positron emission tomography/ magnetic resonance imaging (PET/MRI).

NCT ID: NCT03697161 Completed - Clinical trials for Fragile X Syndrome (FXS)

A Study of OV101 in Individuals With Fragile X Syndrome

ROCKET
Start date: September 17, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and efficacy of oral OV101 (gaboxadol) in subjects with Fragile X syndrome.

NCT ID: NCT02719951 Completed - Healthy Volunteers Clinical Trials

Glutaminergic Transmission in Autism : Molecular Imaging Exploration

TANGAU
Start date: April 2016
Phase: Phase 1
Study type: Interventional

Glutamatergic transmission exploration using PET (Positron Emission Tomography) imaging in autism compared to Fragile-X Syndrome ( FXS) and Healthy Volunteers

NCT ID: NCT02465931 Completed - Clinical trials for Fragile X Syndrome (FXS)

Decisional Capacity and Informed Consent in Fragile X Syndrome

Start date: March 14, 2016
Phase: N/A
Study type: Interventional

The Decisional Capacity and Informed Consent in Fragile X Syndrome (FXS) project is for the Eunice Kennedy Shriver National Institute of Child Health & Human Development, 1R01HD071987-01A1, and will provide the first comprehensive description of decisional capacity of individuals with FXS; identify individual, family, and experiential factors associated with variability in decisional capacity; determine the validity of caregiver and expert ratings; and develop evidence-based guidelines for categorizing decisional capacity of individuals with FXS. The researchers will develop a methodologically rigorous and conceptually grounded decision aid using digital technology to enhance participation of individuals with FXS in the consent process.